pSivida eyes Iluvian
Friday, 13 March, 2009
pSivida has reported good interim results in its Phase II study of the intra-vitreal insert Iluvien.
The 36-month open label study is being conducted by pSivida’s licensing partner Alimera Sciences and is being run concurrently with a Phase III trial of a corticosteroid in patients with diabetic macular oedema.
Data from the first 12 months showed no adverse events in lose dose patients while there was a small increase in intra-ocular pressure in high dose patients.
Iluvian delivers the drug fluocinolone acetonide directly into the eye. pSivida has licensed two other ophthalmic products, Retisert and Vitrasert, to Bausch & Lomb.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
